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Abstract
Background: A hypoxic-ischaemic insult occurring around the time of birth may result in an
encephalopathic state characterised by the need for resuscitation at birth, neurological depression,
seizures and electroencephalographic abnormalities. There is an increasing risk of death or
neurodevelopmental abnormalities with more severe encephalopathy. Current management
consists of maintaining physiological parameters within the normal range and treating seizures with
anticonvulsants.
Studies in adult and newborn animals have shown that a reduction of body temperature of 3–4°C
after cerebral insults is associated with improved histological and behavioural outcome. Pilot
studies in infants with encephalopathy of head cooling combined with mild whole body hypothermia
and of moderate whole body cooling to 33.5°C have been reported. No complications were noted
but the group sizes were too small to evaluate benefit.
Methods/Design: TOBY is a multi-centre, prospective, randomised study of term infants after
perinatal asphyxia comparing those allocated to "intensive care plus total body cooling for 72
hours" with those allocated to "intensive care without cooling".
Full-term infants will be randomised within 6 hours of birth to either a control group with the rectal
temperature kept at 37 +/- 0.2°C or to whole body cooling, with rectal temperature kept at 33–
34°C for 72 hours. Term infants showing signs of moderate or severe encephalopathy +/- seizures
have their eligibility confirmed by cerebral function monitoring. Outcomes will be assessed at 18
months of age using neurological and neurodevelopmental testing methods.
Sample size: At least 236 infants would be needed to demonstrate a 30% reduction in the relative
risk of mortality or serious disability at 18 months.
Recruitment was ahead of target by seven months and approvals were obtained allowing
recruitment to continue to the end of the planned recruitment phase. 325 infants were recruited.
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Primary outcome: Combined rate of mortality and severe neurodevelopmental impairment in
survivors at 18 months of age. Neurodevelopmental impairment will be defined as any of:
• Bayley mental developmental scale score less than 70
• Gross Motor Function Classification System Levels III – V
• Bilateral cortical visual impairments
Trial Registration: Current Controlled Trials ISRCTN89547571
Background
This is a multicentre prospective randomised controlled
trial to determine whether a reduction of body tempera-
ture by 3–4°C following perinatal asphyxia improves sur-
vival without neurodevelopmental disability. Full term
infants will be randomised within 6 hours of birth to
either a control group with the rectal temperature kept at
37 ± 0.2°C or to whole body cooling with the rectal tem-
perature kept at 33.5 ± 0.5°C for 72 hours followed by
slow rewarming. The outcome will be assessed at 18
months of age by survival and neurological and neurode-
velopmental testing.
Hypothesis
Prolonged whole body cooling in term infants with peri-
natal asphyxial encephalopathy reduces death and severe
neurodevelopmental disability.
Perinatal asphyxial encephalopathy
A hypoxic-ischaemic insult occurring around the time of
birth may result in an encephalopathic state characterised
by the need for resuscitation at birth, neurological depres-
sion, seizures and electroencephalographic abnormalities.
There is an increasing risk of death or neurodevelopmen-
tal abnormalities with more severe encephalopathy [1].
Pathogenesis of perinatal asphyxial encephalopathy
Experimental studies [2-4] have shown that a severe peri-
natal hypoxic-ischaemic insult (HII) results in an evolving
process of adverse biochemical events that include
increased levels of neurotransmitters, excessive produc-
tion of free radicals, increased intracellular calcium, and
stimulation of inflammatory mediators and messengers
that initiate apoptotic cell death.
Alterations in cerebral energy metabolism can be
observed during and following HII. During HII cerebral
metabolism is impaired and cerebral high-energy phos-
phate levels fall precipitously. Following termination of
the insult, cerebral energy metabolism initially recovers
but may then deteriorate 6–24 hours later. This secondary
energy failure is not contingent on impaired substrate
supply and its severity is related to survival, head growth
and neurodevelopmental outcome at 1 and 4 years [5-7].
Although the secondary phase of impaired cerebral energy
metabolism resolves after about 72 hours, a persistent dis-
turbance may be detected for several months [8,9].
Current management of perinatal asphyxial 
encephalopathy
No specific treatments are presently available. Current
management consists of maintaining physiological
parameters within the normal range and treating seizures
with anticonvulsants.
Experimental treatments
Several pharmacological agents have shown benefit in
small animal models of hypoxic ischaemic injury [10-12].
However, these observations may have limited relevance
to the clinical situation, where the onset and severity of
the insult are poorly defined and prophylactic treatment is
not feasible. This may explain the lack of benefit of agents
such as calcium channel antagonists and magnesium in
term infants [13].
Recently, pilot studies of hypothermia, phenobarbitone
and allopurinol have been reported. Although the severity
of seizures was not influenced, very early treatment with
high dose phenobarbitone reduced handicap at 3 years
[14]. High dose allopurinol improved electroencephalo-
graphic (EEG) activity and reduced free radical formation
in 22 neonates, but long-term outcomes were not assessed
[15]. However, previous studies have not consistently
shown benefit [16].
Experimental treatment with hypothermia
Studies in adult and newborn animals have shown that a
reduction of body temperature of 3–4°C after cerebral
insults is associated with improved histological and
behavioral outcome [17-19]. Several mechanisms may
help explain these benefits: the increases in extracellular
glutamate and free radical and nitric oxide synthesis are
suppressed [2], cerebral energy phosphates are preserved
and cerebral alkalosis and lactate reduced [3,20]. Mild
hypothermia may also suppress the activation of micro-
glia [21-23]. These changes may preserve cerebral energy
metabolism, reduce cytotoxic cerebral oedema and intrac-
ranial pressure and inhibit apoptosis.
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Timing of hypothermia treatment
Factors that may critically affect the therapeutic response
to hypothermia are the interval between the insult and
initiation of hypothermia, the severity of the insult and
the duration and depth of hypothermia. Most studies
indicate that the maximum benefit occurs when treatment
is started within six hours of the insult [17,24], although
limited neuroprotection has been observed when hypo-
thermia is started as late as 12 hours. Therefore, hypother-
mic treatment following perinatal asphyxia will need to
be started as soon as practically possible. Limited benefit
only might be expected if treatment is delayed beyond six
hours after birth.
Duration of treatment with hypothermia
The duration of treatment with hypothermia has varied
greatly in experimental studies. Consistently beneficial
effects have been observed when moderate hypothermia
was maintained for 12–24 hours, but it has been sug-
gested that treatment up to 72 hours may be required if
the interval before inducing hypothermia is prolonged or
milder degrees of hypothermia are employed [25]. A
rebound rise in epileptiform activity in fetal lambs [25]
and in intracranial pressure in adults with stroke [26] have
been reported when hypothermia was discontinued
before 72 hours.
Clinical trials of treatment with hypothermia
Preliminary studies in adults of whole body hypothermia
following head injury [27], cardiac arrest [28-30] and
stroke [26] have suggested benefit. In 2001 a systematic
review of treatment of head injury with whole body hypo-
thermia failed to demonstrate benefit but this may have
been due to inconsistencies in clinical management
[31,32].
In neonates, hypothermia was first reported as therapy for
resuscitation, before modern resuscitation techniques
were introduced. Pilot studies in infants with encephalop-
athy of head cooling combined with mild whole body
hypothermia and of moderate whole body cooling to
33.5°C have been reported [33-35]. No complications
were noted but the group sizes were too small to evaluate
benefit.
Potential adverse effects of hypothermia
The risk of adverse effects of hypothermia is a critical
issue, given the poor outcome conventionally associated
with hypothermia [36,37]. Impaired cardiac function, dis-
ordered coagulation and increased sepsis have been
reported with profound hypothermia. Thrombocytope-
nia, hypokalaemia and increased sepsis have been noted
in studies of hypothermia to 33°C in adults, but these
were not associated with an adverse outcome [26]. The
metabolic rate is reduced during hypothermia and this
results in bradycardia and prolonged PR and QT intervals.
However, significant arrhythmia has only been reported
in adults with head injury when the rectal temperature is
less than 32°C [38].
There are few data on the safety of mild or moderate hypo-
thermia in newborn infants since previous studies
employed hypothermia for brief periods in the treatment
of failed resuscitation [39-42]. These early studies
appeared to demonstrate improved outcomes without
side effects but few controls were included.
No clinically significant adverse effects due to cooling
were observed in the recent pilot studies of whole body
cooling following encephalopathy [34,35]. As expected,
the heart rate reduced to below 100 bpm with cooling but
this was not accompanied by arrhythmia, and the blood
pressure and perfusion were maintained.
Selective or whole body cooling
Although some experimental evidence suggests that selec-
tive head cooling may be effective [25,43], it is uncertain
whether head cooling alone effectively lowers deep brain
temperature. In anaesthetized piglets, which have a much
smaller head than the human newborn infant, it was pos-
sible to cool the basal ganglia 5°C more than rectal tem-
perature [44]. In adults, a steep temperature gradient has
been observed between the surface of the head and deep
brain structures and the deep brain temperature remains
very close to core temperature even when extreme cold is
applied to the surface of the head [45]. The possibility of
temperature gradients within the brain and the impor-
tance of damage to deep structures in causing severe neu-
rodevelopmental impairment [46] and the lack of precise,
non-invasive methods for measuring regional brain tem-
perature pose major difficulties with selective head cool-
ing.
Pilot studies of whole body hypothermia in neonates
Pilot studies of prolonged whole body cooling in infants
with perinatal asphyxial encephalopathy have been car-
ried out [34,35]. Infants were selected on staged criteria
based on the clinical condition at birth and abnormal
amplitude integrated EEG (aEEG). These criteria have pre-
viously been shown to have > 70% positive predictive
value for death or severe neurodevelopmental disability
[47]. Selection was completed, written informed consent
was obtained and hypothermic treatment started within
six hours of birth, including the infants born outside the
study centres. Rectal temperature was maintained at 33–
34°C for 48–72 hours.
An increase in blood pressure and a reduction in heart rate
with cooling were noted, but these were not clinically sig-
nificant, unless there was an inadvertent rapid change in
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body temperature [34]. A mild hypokalaemia was com-
monly observed. No disturbance in coagulation or viscos-
ity attributable to cooling was seen.
Magnetic resonance imaging (MRI) was performed repeat-
edly. Sinus thrombosis was observed in two infants and
one infant developed delayed haemorrhagic cerebral inf-
arction. These three infants died after intensive care was
withdrawn according to parental wishes when the clinical,
EEG and MRI findings indicated severe, irreversible cere-
bral injury.
Clinical trials of hypothermia in neonates
Since the TOBY trial was started in 2002, three other trials
of hypothermia for the management of neonatal enceph-
alopathy (NE) (one using selective head cooling and two
using whole body cooling), have been published [73-75].
The results of these trials are summarised here with a
reminder of the assumptions that were made when calcu-
lating the required sample size of the TOBY study:
Table 1: Summary of published hypothermia trials, 
showing effect size
Despite the promising results which are beginning to
emerge from the completed studies, none of the com-
pleted or on-going studies (including TOBY) are large
enough to allow assessment of moderate differences after
18 months of age. There is increasing concern that thera-
peutic hypothermia may be introduced into clinical prac-
tice without any knowledge of whether these apparent
initial benefits are maintained in the longer term, such as
at 6 years of age.
There is broad support for continuing to recruit to the on
going trials: a meeting convened by the NIH in Washing-
ton to assess future studies of treatment with hypothermia
in neonates concluded that:
• "Hypothermic treatment for birth asphyxia is not a
standard of care but an investigational treatment with
promise of benefit;"
• "There was agreement that current randomised control-
led trials should be completed and a high priority was put
upon this essential data and continuation of the ongoing
trials was believed to be essential;"
• "It was agreed that long term follow-up data were essen-
tial and strongly advocated."
Early identification of infants at risk of perinatal asphyxial 
encephalopathy Clinical features
Perinatal asphyxial encephalopathy is reported to occur in
between one and two infants per thousand deliveries, and
much more frequently in countries without adequate
obstetric facilities. Early identification by clinical features
of infants at risk of developing encephalopathy is difficult.
Fetal heart rate patterns are not very helpful [48,49] and
neither the Apgar scores recorded immediately after birth
[50,51] nor umbilical cord blood gas analysis [52,53] are
good predictors of the likelihood or severity of post
asphyxial encephalopathy. However, a continuing need
for resuscitation and acidaemia with a cord blood pH <
7.0, are considered essential features of perinatal
asphyxia.
Neuroimaging
Abnormal appearances can be observed on cranial ultra-
sonography, computerized tomography [54] and MRI
[55]. However, these abnormalities may not be apparent
during the first 24 – 48 hours after birth. Therefore, these
techniques may be of use as prognostic indicators but not
for early selection of infants for neuroprotective therapies.
Amplitude integrated EEG (aEEG)
Standard electroencephalography (EEG) and measure-
ment of evoked potentials may provide objective evidence
for abnormal cerebral function following perinatal
asphyxia [56,57]. However, these techniques are difficult
to apply very soon after birth.
Continuous aEEG during the first six hours after birth pro-
vides a more simple objective measure for the presence of
encephalopathy [57,58]. The aEEG records a single chan-
nel EEG from 2 biparietal electrodes. The filtered signal,
containing the main EEG frequencies, is rectified,
smoothed and amplitude integrated before it is written
out, at the bedside on slow-speed paper (6 cm/hour). It is
easier to interpret the aEEG than the conventional EEG,
although it gives less information on the underlying type
of activity.
Table 1: Summary of published hypothermia trial, showing effect size
Name of trial Number in trial Primary outcome and main secondary outcome Effect size [assumed for TOBY]
Cool cap trial 218 Death or severe impairment at 18 months RR 0.82 95%CI 0.66–1.02
NICHD Trial 208 Death or any impairment at 18 months RR 0.73 95%CI 0.56–0.95
Eicher 65 Death or severe impairment at 12 months RR 0.62 95%CI 0.41–0.92
TOBY 236 Death or severe impairment at 18 months [RR 0.70]
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There is a good correlation between early continuous
amplitude monitoring and the conventional EEG [47,59].
The background aEEG pattern after perinatal asphyxia is
reported to accurately predict the outcome in 91% of
infants with low Apgar scores. This represents a positive
predictive value for adverse outcome of approximately
80% [47,57]. When recordings were performed during the
first 3 postnatal hours, the positive predictive value was
75%. However, only 6 of 37 infants showed a change in
aEEG pattern between 3 and 6 hours after birth [53]. Most
of the infants showing a change from the initial aEEG
showed an improvement.
Only infants with a moderately or severely abnormal
aEEG defined using a semiquantitative classification sys-
tem [47] will be recruited to TOBY. Such patients show
aEEG background activity with the upper margin below
10 microvolts and/or a lower margin below 5 microvolts.
There was an excellent correlation (Kappa 0.87) between
the scores of two paediatric registrars who had received
minimal training in the use of these criteria and an expert
[47].
Selection criteria for study entry
The use of multiple clinical risk factors as entry criteria
would ensure that most babies recruited have perinatal
asphyxia. However, the sensitivity would be low, so most
of the babies with perinatal asphyxia would be missed
[52,60]. A more effective approach is to combine an initial
screening test such as severe acidosis or low Apgar score at
birth (< 5 at 5 or 10 min), with abnormal neurological
signs and abnormal amplitude integrated EEG recordings
during the first few hours of life.
Duration of Follow-up
The minimum duration of follow-up that is required for
accurately diagnosing neuromotor, neurosensory and
cognitive disability is 18 months. Long-term follow-up to
at least 6 years of age will also be desirable, as a secondary
study, for detailed assessment of intellectual function.
There is now strong experimental evidence in studies of
adult and immature animals that the short term histolog-
ical and behavioural neuroprotection seen with pro-
longed post-insult hypothermia [61,62] leads to long
lasting neuroprotection associated with corresponding
functional improvement [17,63-65]. Such long lasting
functional neuroprotection has been reported despite up
to 6 hours delay in initiating cooling in adult animal
models [64-66].
Clinical data from follow-up of adults and children sub-
jected to deep hypothermia during surgery have found no
evidence for delayed adverse effects [67,68].
Methods/Design
This will be a multi-centre, prospective, randomised study
of term infants after perinatal asphyxia comparing those
allocated to "intensive care plus total body cooling for 72
hours" with those allocated to "intensive care without
cooling". Clinical staff will be unblinded because they
must know the rectal temperature of the infants in order
to adjust the cooling and heating appropriately. The pri-
mary outcome measure (severe neurodevelopmental dis-
ability) will be assessed blind to allocation.
Inclusion criteria
The infant will be assessed sequentially by criteria A, B and
C listed below:
A. Infants ≥ 36 completed weeks gestation admitted to the
NICU with at least one of the following:
• Apgar score of ≤ 5 at 10 minutes after birth
• Continued need for resuscitation, including endotra-
cheal or mask ventilation, at 10 minutes after birth
• Acidosis within 60 minutes of birth (defined as any
occurrence of umbilical cord, arterial or capillary pH <
7.00)
• Base Deficit ≥ 16 mmol/L in umbilical cord or any blood
sample (arterial, venous or capillary) within 60 minutes
of birth
Infants that meet criteria A will be assessed for whether
they meet the neurological abnormality entry criteria (B)
by trained personnel:
B. Moderate to severe encephalopathy, consisting of
altered state of consciousness (lethargy, stupor or coma)
AND at least one of the following:
• hypotonia
• abnormal reflexes including oculomotor or pupillary
abnormalities
• absent or weak suck
• clinical seizures
Infants that meet criteria A & B will be assessed by aEEG
(read by trained personnel):
C. At least 30 minutes duration of aEEG recording that
shows abnormal background aEEG activity or seizures.
There must be one of the following:
BMC Pediatrics 2008, 8:17 http://www.biomedcentral.com/1471-2431/8/17
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• normal background with some seizure activity
• moderately abnormal activity
• suppressed activity
• continuous seizure activity
Exclusion criteria
• Infants expected to be > 6 hours of age at the time of ran-
domisation
• Major congenital abnormalities, such as diaphragmatic
hernia requiring ventilation, or congenital abnormalities
suggestive of chromosomal anomaly or other syndromes
that include brain dysgenesis
Every effort will be made to ensure entry to the study
before 3 hours of age. Delays should be avoided because
there may be rapid attenuation of neuroprotection with
delay in the start of cooling [69-71].
Consent
Informed written consent will be obtained from a parent
after a full verbal and written explanation of the study.
The attending physician will meet with parents during the
intervention period to ensure that they understand the
study procedures and continue to consent to participate in
the study.
Approval for the study has been obtained from the Lon-
don Multicentre Research Ethics Committee and the Local
Research Ethics Committee of each participating hospital.
Randomisation
Patient allocation will be by central telephone randomisa-
tion, provided by the National Perinatal Epidemiology
Unit (NPEU). As soon as parental consent has been
obtained for an eligible infant, the recruiting TOBY clini-
cian will telephone the randomisation service and obtain
treatment assignment, which will be either to "intensive
care with cooling" or "intensive care". Minimisation will
be used to ensure balance between the groups with respect
to severity of encephalopathy.
All infants recruited to the study will be cared for in a ter-
tiary referral centre that has the equipment necessary for
providing hypothermia treatment to the "intensive care
with cooling" group ("Treatment Centres"). Infants may
be recruited from hospitals that transfer babies to these
centres. Babies that are thought to be eligible will be
assessed by trained retrieval teams from the referral cen-
tres, who will perform the aEEG, seek consent if eligible,
telephone the randomisation service and begin the cool-
ing treatment, if allocated (see TOBY Handbook for more
details).
Clinical management
1. Intensive care group
All infants who are randomised to this group will receive
the present standard of clinical care. Infants will thus
receive symptomatic therapy aimed at homeostasis. In
particular, the management of the temperature of the
infants will aim to maintain normothermia. All infants
will be dried at birth, and kept warm during resuscitation.
The infants will be cared for under an overhead radiant
heater or in closed incubators, servo controlled to the
infants' abdominal skin temperature, to maintain the rec-
tal temperature at 37.0°C ± 0.2°C. Infants born in refer-
ring hospitals that are randomised to this group will be
transferred to the Treatment Centre. The incubator heater
will be adjusted during transport to maintain a rectal tem-
perature as close to 37.0°C as possible.
2. Intensive care with cooling group
All infants randomised to intensive care with cooling will
be treated in closed incubators to facilitate cooling. Hypo-
thermia will be maintained using the Tecotherm cooling
system, which induces hypothermia by circulating fluid
within a special mattress. A temperature thermostat can be
regulated to alter the temperature of the fluid. Typically
the thermostat should be set at 25–30°C to achieve a tar-
get rectal temperature of 33–34°C.
Infants born outside Treatment Centres who are allocated
to intensive care with cooling will be nursed prior to trans-
fer with the overhead radiant warmer turned off. During
transport the infant will be nursed in a transport incuba-
tor. The incubator heater will be turned on and adjusted if
necessary to maintain the rectal temperature between 33
and 34°C. Cooled gel packs will be placed around the
infant if necessary to maintain the target temperature.
Some referring hospitals may have quick access to a Treat-
ment Centre. If it is likely that the infant can be transferred
within three hours of birth, assessment and randomisa-
tion may be postponed until admission to the Treatment
Centre. These infants will receive the normal standard of
care, including maintaining a rectal temperature of 37 ±
0.2°C, during the transfer
Rewarming Procedures
When cooling is concluded 72 hours after randomisation,
or earlier if clinical circumstances dictate, the rectal tem-
perature will be allowed to rise by no more than 0.5°C per
hour, to 37 ± 0.2°C. The thermostat set point of the Teco-
therm system will be adjusted as needed, to rewarm the
infants. The infants' temperature will be carefully moni-
BMC Pediatrics 2008, 8:17 http://www.biomedcentral.com/1471-2431/8/17
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tored for at least 4 hours to prevent rebound hyperther-
mia, as this might be detrimental [71,72].
Discontinuing cooling treatment
Cooling may be discontinued if any of the following
occurs:
• Parents request that cooling be withdrawn prior to 72
hours after randomisation. This decision should be made
in discussion with the TOBY Clinician whenever possible.
• Attending clinician withdraws cooling. Reasons will be
recorded, and might include clinical, EEG and imaging
evidence of severe, irreversible brain injury, or continued
inability to maintain rectal temperature in the desired
range.
• Baby receives extra-corporeal membrane oxygenation
(ECMO).
If the parents or the attending paediatrician elect to dis-
continue cooling, then rewarming and follow-up proce-
dures will be commenced. Apparent improvement on
continuous aEEG recording, after trial entry, is not an
indication for discontinuing cooling.
3. Both groups
Treatment centres will provide a uniform standard of clin-
ical care, to minimise potential bias that could arise from
differential use of co-interventions. Following resuscita-
tion, ventilatory requirement will be judged by assessing
the infant's spontaneous breathing efforts and blood gas
analysis. Infants who appear distressed will receive stand-
ard sedation. Seizures (whether noted on aEEG or clini-
cally) will be treated using a standardised approach.
Blood electrolyte analysis, urine volume and analysis and
infant weight will be monitored to guide fluid manage-
ment. See the TOBY Handbook for more details.
Outcomes
Primary Outcome
• Combined incidence of mortality and severe neurode-
velopmental disability in survivors at 18 months of age.
Neurodevelopment will be assessed, blind to study group,
by a developmental paediatrician. Severe neurodevelop-
mental disability will be defined as the presence of at least
one of:
• Bayley mental development scale (MDI) score < 70
• Gross motor function (GMF) neuromotor impairment
Level 3–5
• Bilateral cortical visual impairment
Secondary Outcomes





5. Prolonged blood coagulation time




10. Major venous thrombosis
11. Renal failure treated with dialysis
12. Pneumonia
13. Pulmonary air leak
14. Duration of hospitalisation
Long term (at 18 months)
1. Mortality
2. Severe neurodevelopmental disability
3. Multiple handicaps (defined as the presence of any two
of the following in an infant; neuromotor disability (Level
3–5 on GMF classification), mental delay (Bayley MDI
score < 70), epilepsy, cortical visual impairment, sen-
sorineural hearing loss)
4. Bayley PDI score
5. Sensorineural hearing loss: ≥ 40 dB
6. Epilepsy (defined as recurrent seizures beyond the neo-
natal period, requiring anticonvulsant therapy at the time
of assessment)
7. Microcephaly (head circumference more than 2 stand-
ard deviations below the mean).
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Data collection
Short-term outcomes (up to discharge from hospital) will
be assessed from hospital notes. Major morbidity at 18
months will be assessed by a research paediatrician, blind
to study allocation, using a standardised neurological
examination and the revised Bayley Scales of Infant Devel-
opment (BSID-II).
Analysis
The relative risks of outcomes between the intensive care
with cooling group and the intensive care group will be
calculated, along with 95% confidence intervals.
Subgroup analyses will be carried out stratifying by:
(a) severity of encephalopathy at study entry (graded
moderate or severe based on pre-specified aEEG criteria);
(b) interval from birth to randomisation (0–2 hours, 2–4
hours, 4–6 hours)
Interim analyses
An independent Data Monitoring and Ethics Committee
(DMEC) will be established, whose remit will be to review
the study's progress. The DMEC will be independent of
the trial organisers. Interim analyses will be supplied, in
strict confidence, to the DMEC, as frequently as its Chair
requests. Meetings of the committee will be arranged peri-
odically, as considered appropriate by the Chair. In the
light of interim data on the trial's outcomes, adverse event
data, accumulating evidence from the NICHD study (see
below) and any other relevant evidence (including
updated overviews of the relevant randomised controlled
trials), the DMEC will inform the Trial Steering Commit-
tee (TSC) if in their view (i) there is proof beyond reason-
able doubt that the data indicate that any part of the
protocol under investigation is either clearly indicated or
contra-indicated, either for all infants or for a particular
subgroup of trial participants or (ii) it is evident that no
clear outcome will be obtained. Appropriate criteria for
proof beyond reasonable doubt cannot be specified pre-
cisely. A difference of at least 3 standard deviations in the
interim analysis of a major endpoint may be needed to
justify halting, or modifying, such a study prematurely. If
this criterion were to be adopted, it would have the prac-
tical advantage that the exact number of interim analyses
would be of little importance, and so no fixed schedule is
proposed. Unless modification or cessation of the study is
recommended by the DMEC, the TSC, investigators, col-
laborators and administrative staff (except those who sup-
ply the confidential information) will remain ignorant of
the results of the interim analysis. Collaborators and all
others associated with the study, may write to the DMEC
via the TOBY Co-ordinating Centre, to draw attention to
any concern they may have about the possibility of harm
arising from the treatment under study, or any other rele-
vant matters.
The DMEC will liaise closely with a related trial of whole
body cooling being conducted by the NICHD in the
United States. This trial uses the same intervention but dif-
ferent eligibility criteria. Its results are likely to be relevant
to decisions about continuation of recruitment to TOBY.
The membership of the DMEC is:
Professor Richard Cooke (Chair)
Dr Ann Johnson (Developmental Paediatrician)
Dr Sam Richmond (Neonataologist)
Dr Hugh Davies (Paediatrician and former MREC Chair-
man)
Dr Pat Yudkin (Statistician)
Serious adverse event reporting
All unexpected serious adverse events will be reported to
the TOBY co-ordinating centre at the National Perinatal
Epidemiology Unit in Oxford within 24 hours. The study
administrator will inform the Chair of the Data Monitor-
ing and Ethics Committee and the Multicentre Research
Ethics Committee of any serious adverse events.
Sample size
The overall rate of the primary outcome in the non cooled
group is assumed to be approximately 70%. A sample size
of 188 infants will be necessary to detect a 30% relative
risk reduction between the cooled and non cooled groups,
at a significance level of 5% and with 80% power. The
incidence of the primary outcome in the cooled group
would be 49%. Allowing for a rate of loss to follow up of
10%, 207 infants will need to be recruited to reach this
target.
However, this calculation needs to be modified to ensure
that meaningful subgroup analyses can be performed for
both infants with moderate and severe encephalopathy.
The event rates of the primary outcome will be approxi-
mately 100% for infants with a severely abnormal aEEG,
and about 60% for infants in the moderately abnormal
group. Each subgroup needs to be large enough to detect
a relative risk between the cooled and non cooled groups
of about 0.6. For the moderately abnormal subgroup, the
sample size required for 80% power will be 150.
It is expected that about 70% of infants will be in the
moderately abnormal subgroup, so to ensure that 150 will
be recruited to this subgroup, the total sample size will be
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214. This would mean that 64 recruits would be in the
severely abnormal subgroup, a sufficient number to detect
the same difference in this subgroup with greater than
80% power. Allowing for 10% loss to follow up, the orig-
inal total sample size to be recruited is 236.
Discussion
Originally, it was the intention in the TOBY study to
recruit a similar number of infants as the completed and
other on-going studies (approximately 200 infants).
Although there is an intention to continue further follow-
up in the other studies, because of the difficulty of such
follow-up, neither study will have recruited sufficient
infants to enable assessment of the effect of cooling on
outcome beyond 18 months of age. TOBY was in a unique
position to ensure that a sufficient cohort of children is
recruited to enable longer-term follow-up at age 6 years.
As the aim of whole body cooling in this group of babies
is to provide neuroprotection, IQ is the most appropriate
primary outcome of a long term follow-up study. IQ is
standardised to 100 for "normal" children. However, in
this group of children we can anticipate that IQ in either
group is unlikely to approximate to the normal. In the
small number of follow up studies that have assessed IQ
in children with NE, the degree of later impairment is
closely correlated with the degree of encephalopathy. For
example, at age 8 years a group of 56 children born with
mild encephalopathy had a mean IQ similar to their peer
group (106 versus 112, using the Wechsler Intelligence
Scales). In the 84 children with moderate encephalopathy
the mean IQ was 95 (standard deviation 23) and for the 5
children with severe encephalopathy the mean IQ was 68
(standard deviation 21) [76].
One standard deviation below the mean for normal chil-
dren is an IQ of 85. If we assume a mean of 85 in the non-
cooled group of TOBY, with a standard deviation of 20,
and wish to be able to detect half a "normal" standard
deviation difference (i.e. 7.5), then this calculation will
require 224 surviving children in total. The current mor-
tality of babies recruited to TOBY is approximately thirty
per cent. If this continues (and there are likely to be a
small number of additional later deaths) and we assume
an eighty per cent follow-up rate, then the required
recruited sample size will need to be 400. However, rela-
tively small changes in some of these assumptions, partic-
ularly the standard deviation of IQ, results in a wide
variation in the number of survivors required to be able to
detect the required difference.
This table of total trial sample sizes varies some of these
assumptions to explore the effect on the sample size
required:
Table 2: Variations in mean IQ, standard deviations and 
mortality rates: their affect on sample size calculation
From these calculations, it appeared reasonable to suggest
that the total trial sample size was increased from 236
infants to around 400 infants, to be sure that the trial had
sufficient power to address important longer-term out-
comes required to affect clinical practice. Otherwise it was
likely that the trial would be underpowered to assess even
modest differences (half a "normal" standard deviation)
in IQ. Although the MRC declined to extend the study end
date, because enrolment into TOBY exceeded expectation,
325 infants were finally enrolled into TOBY, which




The Trial Steering Committee (TSC) will provide overall
supervision of the study on behalf of the Medical Research
Council. Its terms of reference are:
1. To monitor and supervise the progress of the TOBY
study towards its interim and overall objectives.
Table 2: Variations in mean IQ, standard deviations and mortality rates: their affect on sample size calculation.
Total trial size required assuming:
30% mortality 35% mortality
Mean IQ in 
control group




Number required to detect this 









75 15 82.5 15 7.5 126 225 240 243 259
80 15 87.5 15 7.5
85 15 92.5 15 7.5
75 20 82.5 20 7.5 224 400 427 431 460
80 20 87.5 20 7.5
85 20 92.5 20 7.5
75 25 82.5 25 7.5 350 625 667 673 718
80 25 87.5 25 7.5
85 25 92.5 25 7.5
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2. To review at regular intervals relevant information from
other sources (e.g. related studies).
3. To consider the recommendations of the Data Monitor-
ing and Ethics Committee.
4. In the light of 1, 2 and 3 above, to inform the MRC
Council and relevant MRC Research Boards on the
progress of the study.
5. To advise the MRC Council on publicity and the pres-
entation of all aspects of the study.
The TSC will meet a least once per year. Membership of
the TSC is:








The Project Management Group (PMG) will oversee the
day-to-day running of the study, and will consist of the
investigators and the trial staff, based at the TOBY Co-
ordinating Centre (National Perinatal Epidemiology Unit,
Oxford), and the clinical co-ordinating centre (Hammer-
smith Hospital, Imperial College London). The responsi-
bilities of the PMG include:
i) recruitment of participating centres
ii) distribution and supply of data collection forms and
other appropriate documentation for the trial
iii) data collection and management
iv) organisation of the follow-up
v) data entry and cleaning
vi) data analysis
vii) collection of adverse event data
viii) organising and servicing the Data Monitoring and
Ethics Committee.
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